Company intelligence / Profile preview
Fenix Innovation Group
- Ownership
- Private
- Development stage
- Other
Overview
Fenix Innovation Group provides end-to-end R&D, regulatory, and clinical trial management services for biotech/pharma clients. It has played a key role in the development of NTI164, a broad-spectrum cannabinoid therapy now in Phase 2 trials for pediatric neurological disorders. The company specializes in preclinical studies, analytical method development, toxicology studies, and clinical trial execution with a focus on regulatory compliance and commercial readiness.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small moleculeHerbal medicine
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Fenix Innovation Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fenix Innovation Group.